

# MasterClass in Bladder Cancer 2026

**June 9<sup>th</sup>**

Centro de Formación  
y Simulación Avanzada,  
Hospital Universitario 12 de Octubre  
Avda. de Córdoba, s/n. Madrid

## Scientific coordinators:

**Dr. Daniel Castellano**

Medical Oncology Department,  
Hospital Universitario 12 de Octubre, Madrid

**Dr. Félix Guerrero**

Urology Department,  
Hospital Universitario 12 de Octubre, Madrid

## Format:

– In person –

**INSCRIPCIONES AQUÍ**

Organized by:

**HENDERE HEALTHCARE**

**X #BladderMasterClass26**



Hospital Universitario  
12 de Octubre



June 9<sup>th</sup>, 2026

11:00 - 12:00

## Registration

12:00 - 12:15

## Welcome

**Dr. Alfredo Rodríguez**, Head of the Urology Department, Hospital Universitario 12 de Octubre, Madrid

**Dr. Luis Paz-Ares**, Head of the Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid

12:15 - 12:30

## Introduction

**Dr. Félix Guerrero**, Urology Department, Hospital Universitario 12 de Octubre, Madrid

**Dr. Daniel Castellano**, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

12:30 - 12:45

## Keynote lecture – Danae Urogenomics: past, present and future

### Chair:

**Dr. Javier Puente**, Medical Oncology Department, Hospital Clínico San Carlos, Madrid

### Speaker:

**Dra. Marta Dueñas**, CIEMAT - Hospital Universitario 12 de Octubre, Madrid

12:45 - 13:55

## Session 1 – High-Risk Non-Muscle-Invasive Bladder Cancer

### Chairs:

**Dr. Félix Guerrero**, Urology Department, Hospital Universitario 12 de Octubre, Madrid

**Dr. Mario Álvarez**, Urology Department, Hospital Universitario La Paz, Madrid

12:45 - 12:55

## BCG monotherapy is here to stay

**Dr. José Luis Domínguez**, Urology Department, Instituto Valenciano de Oncología, Valencia

12:55 - 13:05

## Systemic immunotherapy is the future

**Dr. Óscar Rodríguez Faba**, Urology Department, Fundació Puigvert, Barcelona

13:05 - 13:15

## Other intravesical therapies will be the winners

**Dr. Evangelos Xylinas**, Urology Department, Hôpital Bichat Claude-Bernard, Paris, France

13:15 - 13:55

## Discussion with a clinical case

**Dr. Mario Hernández**, Urology Department, Hospital Universitario 12 de Octubre, Madrid

13:55 - 14:15

## Keynote lecture – The role of molecular biology in personalizing perioperative treatment

### Chair:

**Dra. Elena Sevillano**, Medical Oncology Department, Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

### Speaker:

**ONLINE** **Dr. Bishoy Faltas**, Weill Cornell University, New York, USA

14:15 - 15:15

 **Lunch**



June 9<sup>th</sup>, 2026

15:15 - 16:25

## **Session 2 – Perioperative treatment in localized muscle-invasive bladder cancer: what should I choose?**

### *Chairs:*

**Dr. Laura S. Mertens**, Urology Department, Netherlands Cancer Institute (NKI), Antoni van Leeuwenhoek Hospital Amsterdam, Países Bajos

**Dr. Fernando Lozano**, Urology Department, Hospital Universitari Vall d'Hebron, Barcelona

15:15 - 15:25

## **Multiparametric MRI for clinical decision making, do we really need TURBT?**

**Dr. Albert Carrión**, Urology Department, Hospital Universitari Vall d'Hebron, Barcelona

15:25 - 15:35

## **Neoadjuvant/perioperative therapy is the best option**

**Dr. Jose Daniel Subiela**, Urology Department, Hospital Universitario 12 de Octubre, Madrid

15:35 - 15:45

## **Adjuvant therapy (guided by liquid biopsy?) is the best option**

**Dr. Álvaro Pinto**, Medical Oncology Department, Hospital Universitario La Paz, Madrid

15:45 - 16:25

## **Discussion with a clinical case**

**Dra. Carmen Gómez del Cañizo**, Servicio de Urología, Hospital Universitario 12 de Octubre, Madrid

16:25 - 16:45

## **Bonus track – Bladder sparing options: past, present and future**

**Dr. Félix Guerrero**, Urology Department, Hospital Universitario 12 de Octubre, Madrid

16:45 - 16:55

## **Discussion**

16:55 - 17:30

## **Coffee break**

17:30 - 19:10

## **Session 3 – Metastatic urothelial carcinoma: the current landscape**

### *Chairs:*

**Dr. Daniel Castellano**, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

**Dr. Guillermo de Velasco**, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

17:30 - 17:40

## **Enfortumab vedotin + pembrolizumab is the standard**

**Dra. María José Juan**, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

17:40 - 17:50

## **Chemotherapy and immunotherapy are the standard**

**Dr. Enrique Grande**, Medical Oncology Department, Hospital Universitario Quirónsalud, Madrid

17:50 - 18:00

## **How do these treatments impact subsequent lines of therapy?**

**Dr. Patrizia Giannatempo**, Istituto Nazionale dei Tumori, Milán (Italia)

18:00 - 18:40

## **Discussion with a clinical case**

**Dr. Jorge Esteban**, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid



June 9<sup>th</sup>, 2026

18:40 - 19:00

## **Bonus track – New molecules and mechanisms of action in preclinical development**

**Dr. Ignacio Durán**, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla  
- IDIVAL, Santander

19:00 - 19:10

## **Discussion**

19:10 - 19:15

## **Closing remarks**

**Dr. Daniel Castellano**, Medical Oncology Department, Hospital Universitario  
12 de Octubre, Madrid

**Dr. Félix Guerrero**, Urology Department, Hospital Universitario 12 de Octubre, Madrid

Secretaría técnica

 **tactics**

 Barcelona · Madrid

 93 451 17 24

 [info@tacticsmd.net](mailto:info@tacticsmd.net)

 [www.tacticsmd.net](http://www.tacticsmd.net)